Merus N.V. vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: Merus N.V. vs Novavax, Inc.

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Merus N.V. and Novavax, Inc. from 2014 to 2023. Over this period, Novavax's SG&A expenses surged by over 2,250%, peaking in 2022, reflecting its aggressive expansion and operational scaling. In contrast, Merus N.V. exhibited a more modest growth of approximately 1,450%, indicating a steady yet strategic approach to managing operational costs. Notably, 2020 marked a pivotal year for both companies, with Novavax's expenses more than quadrupling, likely due to increased activities related to vaccine development. Meanwhile, Merus N.V. maintained a consistent upward trajectory, showcasing its commitment to sustainable growth. This financial narrative underscores the dynamic strategies employed by these biotech firms in navigating the complexities of the industry.